​

Roivant Sciences (ROIV) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

ROIV Stock Forecast

Roivant Sciences (ROIV) stock forecast, based on 16 Wall Street analysts, predicts a 12-month average price target of $47.71, with a high of $55.00 and a low of $41.00. This represents a 27.16% increase from the last price of $37.52.

$15 $23 $31 $39 $47 $55 High: $55 Avg: $47.71 Low: $41 Last Closed Price: $37.52

ROIV Stock Rating

Roivant Sciences stock's rating consensus is Buy, based on 16 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 14 Buy (87.50%), 2 Hold (12.50%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 16 0 2 14 Strong Sell Sell Hold Buy Strong Buy

ROIV Price Target Upside V Benchmarks

TypeNameUpside
StockRoivant Sciences27.16%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-619
Avg Price Target-$48.67$37.79
Last Closing Price$37.52$37.52$37.52
Upside/Downside-29.72%0.72%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 262101--13
Sep, 26291--12
Aug, 26291--12
Jul, 262101--13
Jun, 262101--13
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 16, 2026Stifel Nicolaus$51.00$39.5728.89%35.93%
Sep 09, 2026Yastin SunejaGuggenheim$46.00$41.4810.90%22.60%
Sep 09, 2026UBS$55.00$41.4832.59%46.59%
Sep 08, 2026H.C. Wainwright$47.00$42.0311.82%25.27%
Sep 08, 2026Jefferies$52.00$41.7024.70%38.59%
Aug 07, 2026Douglas TsaoH.C. Wainwright$41.00$35.1216.74%9.28%
May 26, 2026Yastin SunejaGuggenheim$36.00$29.9620.16%-4.05%
May 21, 2026Cowen & Co.$41.00$32.1827.41%9.28%
May 21, 2026David RisingerLeerink Partners$42.00$32.4129.59%11.94%
Apr 16, 2026Piper Sandler$40.00$29.2636.71%6.61%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 21, 2026Cowen & Co.BuyBuyhold
Oct 12, 2026CitigroupBuyBuyhold
Oct 12, 2026Wolfe ResearchBuyPeer Performdowngrade
Sep 24, 2026Cantor FitzgeraldOverweightOverweighthold
Sep 09, 2026GuggenheimBuyBuyhold
Sep 09, 2026Cowen & Co.BuyBuyhold
Sep 08, 2026JefferiesBuyBuyhold
Aug 28, 2026H.C. WainwrightBuyBuyhold
Aug 25, 2026Cantor FitzgeraldOverweightOverweighthold
Aug 10, 2026CitigroupBuyBuyhold

Financial Forecast

EPS Forecast

$-3 $-2 $-1 $0 $1 $2 $3 $4 $5 $6 Mar 23 Mar 24 Mar 25 Mar 26 Mar 27 Mar 28 Mar 29
Mar 23Mar 24Mar 25Mar 26Mar 27Mar 28Mar 29
Reported$-1.42$5.55$-0.24$-0.43---
Avg Forecast$-1.59$5.22$-0.77$-1.09$-1.07$-0.47$0.20
High Forecast$-0.73$5.41$-0.72$-0.81$-0.82$-0.22$0.33
Low Forecast$-2.63$4.98$-0.81$-1.29$-1.39$-0.77$0.09
Surprise %-10.69%6.32%-68.83%-60.55%---

Revenue Forecast

$0 $500M $1B $2B $2B $3B Mar 23 Mar 24 Mar 25 Mar 26 Mar 27 Mar 28 Mar 29
Mar 23Mar 24Mar 25Mar 26Mar 27Mar 28Mar 29
Reported$61.28M$32.71M$29.05M$8.26M---
Avg Forecast$52.28M$181.74M$92.10M$34.74M$61.48M$762.32M$1.57B
High Forecast$78.79M$193.36M$139.48M$59.09M$92.67M$1.15B$2.37B
Low Forecast$30.60M$176.37M$56.33M$17.27M$35.98M$446.16M$920.09M
Surprise %17.22%-82.00%-68.45%-76.23%---

Net Income Forecast

$-3B $-1B $300M $2B $3B $5B Mar 23 Mar 24 Mar 25 Mar 26 Mar 27 Mar 28 Mar 29
Mar 23Mar 24Mar 25Mar 26Mar 27Mar 28Mar 29
Reported$-1.01B$4.35B$-171.98M$-299.77M---
Avg Forecast$-1.32B$4.35B$-605.08M$-804.05M$-911.26M$-387.83M$163.44M
High Forecast$-608.11M$4.50B$-596.22M$-672.44M$-682.96M$-178.73M$271.22M
Low Forecast$-2.19B$4.14B$-670.75M$-1.07B$-1.15B$-643.57M$75.32M
Surprise %-23.53%-0.07%-71.58%-62.72%---

ROIV Forecast FAQ

Is Roivant Sciences stock a buy?

Roivant Sciences stock has a consensus rating of Buy, based on 16 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 14 Buy, 2 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Roivant Sciences is a favorable investment for most analysts.

What is Roivant Sciences's price target?

Roivant Sciences's price target, set by 16 Wall Street analysts, averages $47.71 over the next 12 months. The price target range spans from $41 at the low end to $55 at the high end, suggesting a potential 27.16% change from the previous closing price of $37.52.

How does Roivant Sciences stock forecast compare to its benchmarks?

Roivant Sciences's stock forecast shows a 27.16% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Roivant Sciences over the past three months?

  • October 2026: 15.38% Strong Buy, 76.92% Buy, 7.69% Hold, 0% Sell, 0% Strong Sell.
  • September 2026: 16.67% Strong Buy, 75.00% Buy, 8.33% Hold, 0% Sell, 0% Strong Sell.
  • August 2026: 16.67% Strong Buy, 75.00% Buy, 8.33% Hold, 0% Sell, 0% Strong Sell.

What is Roivant Sciences’s EPS forecast?

Roivant Sciences's average annual EPS forecast for its fiscal year ending in March 2027 is $-1.07, marking a 148.84% increase from the reported $-0.43 in 2026. Estimates for the following years are $-0.47 in 2028, and $0.2 in 2029.

What is Roivant Sciences’s revenue forecast?

Roivant Sciences's average annual revenue forecast for its fiscal year ending in March 2027 is $61.48M, reflecting a 644.32% increase from the reported $8.26M in 2026. The forecast for 2028 is $762.32M, and $1.57B for 2029.

What is Roivant Sciences’s net income forecast?

Roivant Sciences's net income forecast for the fiscal year ending in March 2027 stands at $-911M, representing an 203.99% increase from the reported $-300M in 2026. Projections indicate $-388M in 2028, and $163.44M in 2029.